RxDoctor Payments Data

Donald McCarren, DO

Neurology · Bonita Springs, FLNPI 1255385662

Payments from drug & device makers

$49,917in general payments, 2019–2025

Across 751 payments — averaging $66.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$21K
  • Biogen$6K
  • Corium, LLC$5K
  • Eisai Inc.$5K
  • UCB, Inc.$1K
  • AbbVie$1K
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$9,03518%
  • Speaking & faculty fees$20,90842%
  • Travel & lodging$2,1674%
  • Food & beverage$17,68535%
  • Education$1220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC79$20,594
Biogen58$6,231
Corium, LLC21$5,458
Eisai Inc.50$4,946
UCB, Inc.59$1,332
AbbVie(2 entities)57$1,290
GE HealthCare37$1,025
Alnylam Pharmaceuticals Inc.28$699
Argenx US, Inc.23$575
Neurocrine Biosciences, Inc.19$573
EMD Serono, Inc.25$525
MDD US Operations, LLC7$483
Johnson & Johnson(2 entities)21$470
Amgen21$412
Teva Pharmaceuticals USA, Inc.23$405
Genentech USA, Inc.19$378
Acorda Therapeutics, Inc16$344
Novartis15$328
Otsuka America Pharmaceutical, Inc.11$252
Biohaven Pharmaceuticals, Inc.12$242
Lundbeck LLC11$230
AstraZeneca9$230
Livanova USA, Inc.3$221
Bristol Myers Squibb11$217
Neurelis, Inc.11$212
Sanofi10$194
Life Molecular Imaging Ltd2$185
Sunovion Pharmaceuticals Inc.11$179
Acadia Pharmaceuticals Inc7$149
E.r. Squibb & Sons, L.L.C.2$144
Biohaven Pharmaceutical Holding Company Ltd.6$114
Boston Scientific2$95
Pfizer5$87
Merz Pharmaceuticals, LLC3$83
Shire North American Group Inc5$78
GRT US Holding, Inc.2$68
Amneal Pharmaceuticals LLC4$68
Tanabe Pharma America, Inc.4$67
Mallinckrodt Hospital Products Inc.3$64
Supernus Pharmaceuticals, Inc.4$63
Avanir Pharmaceuticals, Inc.3$62
Zyla Life Sciences, Inc.4$59
Idorsia Pharmaceuticals US Inc3$56
TG Therapeutics, Inc.2$52
Ipsen Biopharmaceuticals, Inc2$37
CSL Behring2$34
Amarin Pharma, Inc.2$31
Adamas Pharmaceuticals, Inc.2$31
Harmony Biosciences LLC1$29
Alfasigma USA, Inc.2$27
Averitas Pharma Inc.1$25
Nevro Corp.1$21
Sanofi-aventis U.S. LLC1$19
Takeda Pharmaceuticals U.S.A., Inc.1$19
Regeneron Healthcare Solutions, Inc.1$18
Avion Pharmaceuticals1$17
Arbor Pharmaceuticals, Inc.1$16
Merck1$13
Promius Pharma LLC1$12
Neos Therapeutics, LP1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,917 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$3,219,468
Medicare patients
581
Services billed
722,544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GocovriAmantadine Hcl15$22,831
OngentysOpicapone26$20,823
BelsomraSuvorexant28$13,150
ExelonRivastigmine14$9,452
Rivastigmine38$4,722
VyvanseLisdexamfetamine Dimesylate11$4,194
Donepezil Hcl362$4,054
Carbidopa-Levodopa ErCarbidopa/Levodopa21$2,048
Memantine Hcl76$1,089
Levetiracetam11$935
Galantamine Hbr18$929
Carbidopa-LevodopaCarbidopa/Levodopa57$846
RivastigmineRivastigmine Tartrate20$683
Naltrexone Hcl15$633
Sertraline Hcl41$556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MDD US Operations, LLCGocovri$483$22,83115 claims
Neurocrine Biosciences, Inc.Ongentys$573$20,82326 claims
MerckBelsomra$13$13,15028 claims
NovartisExelon$328$9,45214 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$19$4,19411 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$68$25711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.

Other neurology in Bonita Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →